We are live on ! Find out more
CEROW

CERo Therapeutics Warrants
CEROW

Delisted

CEROW was delisted on the 30th of October, 2025.

Back to rankings

43 hedge funds and large institutions have $3.72M invested in CERo Therapeutics Warrants in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

50% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 4

5% more funds holding

Funds holding: 41 → 43 (+2)

1% more capital invested

Capital invested by funds: $3.7M → $3.72M (+$20.9K)

Holders
43
Holders Change
+2
Holders Change %
+4.88%
% of All Funds
0.74%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
6
Reduced
4
Closed
2
Calls
$9K
Puts
–
Net Calls
+$9K
Net Calls Change
-$2K

Top Buyers

Rank Fund Capital Flow
1
PC
Periscope Capital
Ontario, Canada
+$53.1K
2
MF
Magnetar Financial
Illinois
+$11.7K
3
BCM
Basso Capital Management
Connecticut
+$3.16K
4
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors
North Carolina
+$2.33K
5
SFM
Spartan Fund Management
Canada
+$2.1K

Top Sellers

Rank Fund Capital Flow
1
FTCM
Fir Tree Capital Management
New York
-$13K
2
HIM
HGC Investment Management
Ontario, Canada
-$4.21K
3
VF
Virtu Financial
New York
-$2K
4
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$303
5
BI
Bulldog Investors
New Jersey
-$136
Name Holding Trade Value Shares
Change 		Change in
Stake
HF
26
HRT Financial
New York
$5K – – –
PMAM
27
Picton Mahoney Asset Management
Ontario, Canada
$5K – – –
HIM
28
HGC Investment Management
Ontario, Canada
$4K -$4.21K -50,000 -50%
Hudson Bay Capital Management
29
Hudson Bay Capital Management
Connecticut
$4K -$303 -3,600 -12%
BI
30
Bulldog Investors
New Jersey
$4K -$136 -1,618 -3%
RCM
31
Rivernorth Capital Management
Florida
$4K – – –
TCM
32
Tenor Capital Management
New York
$4K – – –
SSA
33
Schonfeld Strategic Advisors
New York
$3K – – –
FTUS
34
Flow Traders U.S.
New York
$3K +$705 +8,373 +69%
BCM
35
Basso Capital Management
Connecticut
$3K +$3.16K +37,480 New
DCM
36
Dupont Capital Management
Delaware
$2K – – –
WA
37
Whitebox Advisors
Minnesota
$2K – – –
Calamos Advisors
38
Calamos Advisors
Illinois
$2K +$1.05K +12,500 New
SFM
39
Spartan Fund Management
Canada
$2K +$2.1K +25,000 New
CAPTRUST Financial Advisors
40
CAPTRUST Financial Advisors
North Carolina
$2K +$2.33K +27,699 New
RA
41
Ramius Advisors
New York
$1K – – –
WP
42
Woodline Partners
California
$1K – – –
FTCM
43
Fir Tree Capital Management
New York
– -$13K -125,000 Closed
VF
44
Virtu Financial
New York
– -$2K -15,814 Closed
RCM
45
Robinson Capital Management
Michigan
– +$40 +478 +15%
1
2

CEROW Hedge Fund Activity: Q3 2022 in Review

43 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in CERo Therapeutics Warrants (CEROW) for Q3 2022, worth a combined $3.72M — up 0.57% from $3.7M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new CEROW positions and 2 closed out — a net gain of 2 holders — while 6 added to existing stakes and 4 trimmed.

The largest buyer was Periscope Capital, adding an estimated $53.1K. The largest seller was Fir Tree Capital Management, exiting entirely with an estimated $13K sold.

  • 43 institutional investors held CERo Therapeutics Warrants (CEROW) as of Q3 2022, up from 41 in Q2 2022.
  • Funds reported $3.72M of CERo Therapeutics Warrants stock for Q3 2022, up 0.57% quarter-over-quarter.
  • 4 funds opened new CERo Therapeutics Warrants positions in Q3 2022 and 2 closed out, a net change of +2 holders.
  • The largest CERo Therapeutics Warrants buyer in Q3 2022 was Periscope Capital, an estimated $53.1K added.
  • The largest CERo Therapeutics Warrants seller in Q3 2022 was Fir Tree Capital Management, an estimated $13K sold.

Based on aggregated 13F filings for Q3 2022.